Recursion Pharmaceuticals, Inc. (RXRX) Tops Q3 EPS by 1c
Tweet
Share
E-mailGet Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.36), $0.01 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $16.95 million.
For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
- Lockheed Martin wins $1.08 billion in defense contracts
- American Critical Minerals closes $2.54M private placement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
